

ATTY. DOCKET NO. 1503.1030002/JMC/THN/JSL	APPLICATION NO. 10/058,215
APPLICANT Lu et al.	
FILING DATE January 29, 2002	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

RECEIVED  
TECH CENTER 1600  
NOV 01 2002  
A600/2000

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
KH	AO3	EP 0 623 607 A1	11/09/1994	Europe			Yes No
AP							Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED Aug. 27, 2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED #5

SEP 06 2002



TECH CENTER 1600/2900

APPLICATION NO.  
10/058,215

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1503.1030002/JMC/THN/JSL	
		APPLICANT Lu et al.	
		FILING DATE January 29, 2002	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
KM	A11	6,066,648	05/23/2000	Duggan et al.	514	300	12/15/1998
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
KM	AN3	WO 00/02874	01/20/2000	WIPO			Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

*Att Hwy Ver*

DATE CONSIDERED Aug. 27, 2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1503.1030002APPLICATION NO.  
10/058,215APPLICANT  
Lu et al.FILING DATE  
January 29, 2002GROUP  
1614**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
KN	AA1	5,741,796	04/21/1998	Hartman et al.	514	300	09/26/1996
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**RECEIVED**

JUL 29 2002

TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
KN	AL1	WO 97/06791	02/27/1997	WIPO			Yes No
	AM1	WO 97/23451	07/03/1997	WIPO			X Yes No
	AN1	WO 97/36859	10/09/1997	WIPO			Yes No
	AO1	WO 97/45137	12/04/1997	WIPO			Yes No
	AP1	WO 98/00395	01/08/1998	WIPO			X Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

KN	AR	1	Albelda, S.M., "Biology of Disease. Role of Integrins and Other Cell Adhesion Molecules in Tumor Progression and Metastasis," <i>Lab. Invest.</i> 68:4-17, The United States and Canadian Academy of Pathology, Inc. (1993).
	AS	1	Albelda, S.M. et al., "Integrin Distribution in Malignant Melanoma: Association of the $\beta_1$ Subunit with Tumor Progression," <i>Cancer Res.</i> 50:6757-6764, American Association for Cancer Research (1990).
	AT	1	Batcho, A. et al., "Indoles From 2-Methylnitrobenzenes by Condensation With Formamide Acetals Followed by Reduction: 4-Benzylxyindole (1 H-Indole, 4-(phenylmethoxy)-)," in <i>Organic Synthesis</i> , Saucy, G. et al., Eds., John Wiley & Sons, New York, NY, pp. 214-225 (1985).

EXAMINER

*[Signature]*

DATE CONSIDERED

Aug 27, 2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b> <i>JUL 26 2002</i>			ATTY. DOCKET NO. 1503.1030002		APPLICATION NO. 10/058,215		
			APPLICANT Lu et al.				
			FILING DATE January 29, 2002		GROUP 1614		
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
KH	AL2	WO 98/14192	04/09/98	WIPO			Yes No
KH	AM2	WO 00/33838	06/15/00	WIPO			Yes No
	AN2						Yes No
	AO2						Yes No
	AP2						Yes No
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
KH	AR	2	Boudreau, N. and Rabinovitch, M., "Developmentally Regulated Changes in Extracellular Matrix in Endothelial and Smooth Muscle Cells in the Ductus Arteriosus May be Related to Intimal Proliferation," <i>Lab. Invest.</i> 64:187-199, The United States and Canadian Academy of Pathology, Inc. (1991).				
	AS	2	Brocke, S. et al., "Antibodies to CD44 and integrin $\alpha_4$ , but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment," <i>Proc. Natl. Acad. Sci. USA</i> 96:6896-6901, The National Academy of Sciences (1999).				
	AT	2	Brooks, P.C. et al., "Integrin $\alpha_1\beta_1$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <i>Cell</i> 79:1157-1164, Cell Press (1994).				
EXAMINER <i>A. Myrth</i>					DATE CONSIDERED <i>Aug 27, 2003</i>		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b> <i>JUL 26 2002</i>				ATTY. DOCKET NO. 1503.1030002	APPLICATION NO. 10/058,215		
				APPLICANT Lu et al.			
				FILING DATE January 29, 2002	GROUP 1614		
				<b>U.S. PATENT DOCUMENTS</b>			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
KH	AR	3	Brooks, P.C., "Integrin $\alpha v \beta 3$ : A Therapeutic Target," <i>DN&amp;P</i> 10:456-461, Prous Science (1997).				
	AS	3	Brooks, P.C. et al., "Antintegrin $\alpha v \beta 3$ blocks human breast cancer growth and angiogenesis in human skin," <i>J. Clin. Invest.</i> 96:1815-1822, The American Society for Clinical Investigation, Inc. (1995).				
	AT	3	Brooks, P.C. et al., "Requirement of Vascular Integrin $\alpha, \beta$ , for Angiogenesis," <i>Science</i> 264:569-571, American Association for the Advancement of Science (1994).				
EXAMINER <i>J. May Jr.</i>				DATE CONSIDERED <i>Aug. 27, 2003</i>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 1503.1030002	APPLICATION NO. 10/058,215
		APPLICANT Lu et al.	FILING DATE January 29, 2002
		GROUP 1614	

JUL 26 2002

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

**RECEIVED**

JUL 29 2002

TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

KM	AR	4	Brooks, P.C., "Cell adhesion molecules in angiogenesis," <i>Cancer Met. Rev.</i> 15:187-194, Kluwer Academic Publishers (1996).
	AS	4	Cheresh, D.A., "Structure, function and biological properties of integrin of $\alpha_v\beta_3$ on human melanoma cells," <i>Cancer Met. Rev.</i> 10:3-10, Kluwer Academic Publishers (1991).
	AT	4	Choi, E.T. et al., "Inhibition of neointimal hyperplasia by blocking $\alpha_v\beta_3$ integrin with a small peptide antagonist Gp6GRGDSPCA," <i>J. Vasc. Surg.</i> 19:125-134, The Society for Vascular Surgery and International Society for Cardiovascular Surgery (1994).


EXAMINER

*M. May, Ph.D.*

DATE CONSIDERED

*Aug 27, 2003*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT  <small>JUL 26 2002</small>			ATTY. DOCKET NO. 1503.1030002		APPLICATION NO. 10/058,215		
			APPLICANT Lu et al.				
			FILING DATE January 29, 2002		GROUP 1614		
			U. S. PATENT DOCUMENTS				
EXAMINER INITIALS	SEARCHED	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
		AA					
		AB					
		AC					
		AD					<b>RECEIVED</b>
		AE					<small>JUL 29 2002</small>
		AF					<small>TECH CENTER 1600/2900</small>
		AG					
		AH					
		AI					
		AJ					
		AK					
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
		AL					Yes No
		AM					Yes No
		AN					Yes No
		AO					Yes No
		AP					Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
KH	AR	5	Corey, E.J. and Fuchs, P.L., "A Synthetic Method for Formyl → Ethynyl Conversion (RCHO → RC=CH or RC=CR')," <i>Tetrahedron Lett.</i> 36:3769-3772, Pergamon Press (1972).				
	AS	5	Enenstein, J. and Kramer, R.H., "Confocal Microscopic Analysis of Integrin Expression on the Microvasculature and its Sprouts in the Neonatal Foreskin," <i>J. Invest. Dermatol.</i> 103:381-386, The Society for Investigative Dermatology, Inc. (1994).				
✓	AT	5	Fisher, J.E. et al., "Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, an "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein," <i>Endocrinology</i> 132:1411-1413, The Endocrine Society (1993).				
EXAMINER <i>A. V. H. H.</i>				DATE CONSIDERED <i>Aug. 27, 2003</i>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

OIA FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1503.1030002	APPLICATION NO. 10/058,215
		APPLICANT Lu et al.	
		FILING DATE January 29, 2002	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

KI	AR	6	Friedlander, M. et al., "Definition of Two Angiogenic Pathways by Distinct $\alpha_v$ Integrins," <i>Science</i> 270:1500-1502, American Association for the Advancement of Science (1995).
	AS	6	Gladson, C.L., "Expression of Integrin $\alpha v \beta 3$ in Small Blood Vessels of Glioblastoma Tumors," <i>J. Neuropathol. Exp. Neurol.</i> 55:1143-1149, The American Association of Neuropathologists (1996).
	AT	6	Greene, T.W. and Wuts, P.G.M., "Special -NH Protective Groups. Protection for the Amino Group: Special -NH Protective Groups," in <i>Protective Groups in Organic Synthesis</i> , 2nd edition, John Wiley and Sons, Inc., New York, pp. 267-287 and p. 331 (1991).

EXAMINER


*M. P. J. R. A.*

DATE CONSIDERED

Aug 27, 2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1503.1030002	APPLICATION NO. 10/058,215
		APPLICANT Lu et al.	
		FILING DATE January 29, 2002	GROUP 1614



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

KH	AR	7	Greenspoon, N. et al., "Structural Analysis of Integrin Recognition and the Inhibition of Integrin-Mediated Cell Functions by Novel Nonpeptidic Surrogates of the Arg-Gly-Asp Sequence," <i>Biochemistry</i> 32:1001-1008, American Chemical Society (1993).
	AS	7	Hardan, I. et al., "Inhibition of Metastatic Cell Colonization in Murine Lungs and Tumor-Induced Morbidity by Non-Peptidic Arg-Gly-Asp Mimetics," <i>Int. J. Cancer</i> 55:1023-1028, Wiley-Liss, Inc. (1993).
↓	AT	7	Hendrickson, J.B. and Hussoin, Md. S., "Facile Dehydration of Activated Ketones to Alkynes," <i>Synthesis</i> 3:217-221, Thieme Medical Publishers, Inc. (1989).

EXAMINER

*AB Wm Tax*

DATE CONSIDERED Aug. 27, 2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b> <i>JUL 26 2002 JCB</i>			ATTY. DOCKET NO. 1503.1030002		APPLICATION NO. 10/058,215		
			APPLICANT Lu et al.				
			FILING DATE January 29, 2002		GROUP 1614		
			<b>U.S. PATENT DOCUMENTS</b>				
EXAMINER INITIALS	SEARCHED	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						<b>RECEIVED</b>
	AE						<b>JUL 29 2002</b>
	AF						<b>TECH CENTER 1600/2900</b>
	AG						
	AH						
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
XN	AR	8	Hershkoviz, R. et al., "Inhibition of CD4 <sup>+</sup> T lymphocyte binding to fibronectin and immune-cell accumulation in inflammatory sites by non-peptidic mimetics of Arg-Gly-Asp," <i>Clin. Exp. Immunol.</i> 95:270-276, Blackwell Scientific Publishers (1994).				
	AS	8	Horton, M., "Current Status Review. Vitronectin receptor: tissue specific expression or adaption to culture?," <i>Int. J. Exp. Pathol.</i> 71:741-759, Blackwell Scientific Publications (1990).				
↓	AT	8	Hynes, R.O., "Integrins: Versatility, Modulation, and Signaling in Cell Adhesion," <i>Cell</i> 69:11-25, Cell Press (1992).				
EXAMINER <i>J. My Park</i>					DATE CONSIDERED <i>Aug. 27, 2003</i>		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

INFORMATION DISCLOSURE STATEMENT FORM PTO-1449			ATTY. DOCKET NO. 1503.1030002		APPLICATION NO. 10/058,215		
			APPLICANT Lu et al.				
			FILING DATE January 29, 2002		GROUP 1614		
			U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	SEARCHED	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	JUL 26 2002	AA					
		AB					JUL 29 2002
		AC					SH CENTER 1000/2900
		AD					
		AE					
		AF					
		AG					
		AH					
		AI					
		AJ					
		AK					
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
		AL					Yes No
		AM					Yes No
		AN					Yes No
		AO					Yes No
		AP					Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
KN	AR	9	Juliano, R., "Signal transduction by integrins and its role in the regulation of tumor growth," <i>Cancer Met. Rev.</i> 13:25-30, Kluwer Academic Publishers (1994).				
	AS	9	Kaul, D.K. et al., "Monoclonal antibodies to $\alpha V\beta 3$ (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor," <i>Blood</i> 95:368-374, The American Society of Hematology (January 2000).				
↓	AT	9	Ku, T.W. et al., "Direct Design of a Potent Non-Peptide Fibrinogen Receptor Antagonist Based on the Structure and Conformation of a Highly Constrained Cyclic RGD Peptide," <i>J. Amer. Chem. Soc.</i> 115:8861-8862, American Chemical Society (1993).				
EXAMINER <i>A. J. M. M. A.</i>					DATE CONSIDERED <i>Aug. 27 2003</i>		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b> <i>JUL 26 2002 JCBA</i>		ATTY. DOCKET NO. 1503.1030002	APPLICATION NO. 10/058,215
		APPLICANT Lu et al.	
		FILING DATE January 29, 2002	GROUP 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

**RECEIVED**

JUL 29 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO						Yes No
AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

KN	AR	10	Marquardt, D. W., "An Algorithm for Least-Squares Estimation of Nonlinear Parameters," <i>J. Soc. Indust. Appl. Math.</i> 11:431-441, Society for Industrial and Applied Mathematics (1963).
	AS	10	Mitsunobu, O., "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products," <i>Synthesis</i> 1:1-28, Georg Thieme Verlag (1981).
	AT	10	Nicosia, R.F. and Madri, J.A., "The Microvascular Extracellular Matrix. Developmental Changes During Angiogenesis in the Aortic Ring-Plasma Clot Model," <i>Amer. J. Pathol.</i> 128:78-90, American Association of Pathologists (1987).


EXAMINER

*Att My Thrz*

DATE CONSIDERED

*Aug. 27, 2002*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 1503.1030002		APPLICATION NO. 10/058,215	
		APPLICANT Lu et al.			
		FILING DATE January 29, 2002		GROUP 1614	

JUL 26 2002

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	EXAMINER NAME	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						JUL 29 2002
	AB						TECH CENTER 600/2000
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

KH	AR	11	Niiya, K. et al., "Increased Surface Expression of the Membrane Glycoprotein IIb/IIIa Complex Induced by Platelet Activation. Relationship to the Binding of Fibrinogen and Platelet Aggregation," <i>Blood</i> 70:475-483, Grune & Stratton, Inc. (1987).
	AS	11	Nip, J. et al., "Coordination Expression of the Vitronectin Receptor and the Urokinase-type Plasminogen Activator Receptor in Metastatic Melanoma Cells," <i>J. Clin. Invest.</i> 95:2096-2103, The American Society for Clinical Investigation, Inc. (1995).
	AT	11	Okada, Y. et al., "Integrin $\alpha_v\beta_3$ Is Expressed in Selected Microvessels after Focal Cerebral Ischemia," <i>Amer. J. Pathol.</i> 149:37-44, American Society for Investigative Pathology (1996).

EXAMINER

*Alvin Hu*

DATE CONSIDERED

*Aug 27, 2003*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

O I NFORMATION DISCLOSURE STATEMENT <i>III 26 2002</i> P ATENT INTELLIGENCE OFFICE			ATTY. DOCKET NO. 1503.1030002		APPLICATION NO. 10/058,215		
			APPLICANT Lu et al.		FILING DATE January 29, 2002		
			GROUP 1614				
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							JUL 29 2002
AG							
AH							
AI							
AJ							
AK							
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
AL							Yes No
AM							Yes No
AN							Yes No
AO							Yes No
AP							Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
K1	AR	<u>12</u>	Relton, J.K. et al., "Inhibition of $\alpha 4$ Integrin Protects Against Transient Focal Cerebral Ischemia in Normotensive and Hypertensive Rats," Stroke 32:199-205, American Heart Association, Inc. (January 2001).				
	AS	<u>12</u>	Ruoslahti, E. and Giancotti, F.G., "Integrins and Tumor Cell Dissemination," Cancer Cells 1:119-126, Cold Spring Harbor Laboratory Press (1989).				
	AT	<u>12</u>	Ruoslahti, E. and Reed, J.C., "Anchorage Dependence, Integrins, and Apoptosis," Cell 77:477-478, Cell Press (1994).				
EXAMINER <i>P. Mayhew</i>					DATE CONSIDERED <i>Aug. 27, 2003</i>		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

<p style="text-align: center;">O P E FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u> JUL 26 2002</p>				ATTY. DOCKET NO. 1503.1030002	APPLICATION NO. 10/058,215		
				APPLICANT Lu et al.	FILING DATE January 29, 2002	GROUP 1614	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	TRADEMARKS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
KH	AR	<u>13</u>	Savelon, L. et al., "Substituted pyrido[3,2-b]oxazin-3(4H)-ones: synthesis and evaluation of antinociceptive activity," <i>Bioorganic Med. Chem.</i> 6:133-142, Elsevier Science Ltd. (1998).				
	AS	<u>13</u>	Sato, M. et al., "Echistatin Is a Potent Inhibitor of Bone Resorption in Culture," <i>J. Cell Biol.</i> 111:1713-1723, The Rockefeller University Press (1990).				
↓	AT	<u>13</u>	Shattil, S.J., "Function and Regulation of the B <sub>3</sub> Integrins in Hemostasis and Vascular Biology," <i>Thromb. Haemost.</i> 74:149-155, F.K. Schattauer Verlagsgesellschaft mbH (1995).				
EXAMINER				DATE CONSIDERED <i>Aug. 27, 2007</i>			
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT III 26 2002			ATTY. DOCKET NO. 1503.1030002		APPLICATION NO. 10/058,215		
			APPLICANT Lu et al.		FILING DATE January 29, 2002		
			GROUP 1614				
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	TRADE NAME	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
		AA					
		AB					
		AC					
		AD					
		AE					
		AF					
		AG					
		AH					
		AI					
		AJ					
		AK					
RECEIVED JUL 29 2002 TECH CENTER 1600/2900							
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
		AL					Yes No
		AM					Yes No
		AN					Yes No
		AO					Yes No
		AP					Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
KN	AR	14	Sonogashira, K. et al., "A Convenient Synthesis of Acetylenes: Catalytic Substitutions of Acetylenic Hydrogen with Bromoalkenes, Iodoarenes, and Bromopyridines," Tetrahedron Lett. 50:4467-4470, Pergamon Press (1975).				
	AS	14	Topol, E.J. et al., "Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months," Lancet 343:881-886, The Lancet Ltd. (1994).				
J	AT	14	White, J.M., "Integrins as virus receptors," Curr. Biol. 3:596-599, Current Biology (1993).				
EXAMINER <i>A. May, Ph.D.</i>					DATE CONSIDERED <i>Aug. 27, 2003</i>		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT JUL 26 2002		ATTY. DOCKET NO. 1503.1030002	APPLICATION NO. 10/058,215
		APPLICANT Lu et al.	
		FILING DATE January 29, 2002	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD				1112 A 2002		
	AE						
	AF						600/2900
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

KH	AR	15	Yun, Z. et al., "Involvement of Integrin $\alpha_5\beta_3$ in Cell Adhesion, Motility, and Liver Metastasis of Murine RAW117 Large Cell Lymphoma," Cancer Res. 56:3103-3111, The American Association for Cancer Research (1996).
	AS	15	Chemical Abstracts English language summary of document AM2 (WO 98/00395), CAPLUS Accession Number 1998:38464.
	AT		

EXAMINER	<i>A. R. by Varo</i>	DATE CONSIDERED <i>Aug. 27, 2003</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO-1449 <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> <i>JUL 26 2002</i>			ATTY. DOCKET NO. 1503.1030002/JMC/THN	APPLICATION NO. 10/058,215
			APPLICANT Lu et al.	
			FILING DATE January 29, 2002	GROUP 1614

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
<i>KH</i>	AB1	5,223,517	06/29/1993	Müller et al.	514	339	08/23/1991
	AC1	5,234,942	08/10/1993	Bernstein et al.	514	415	12/17/1990
	AD1	5,290,788	03/01/1994	Stevens et al.	514	314	04/21/1992
	AE1	5,744,488	04/28/1998	Cross et al.	514	339	02/23/1996
	AF1	5,834,454	11/10/1998	Kitano et al.	514	183	01/28/1997
	AG1	5,977,100	11/02/1999	Kitano et al.	514	214	05/08/1998
<i>✓</i>	AH1	6,184,238 B1	02/06/2001	Takano et al.	514	339	06/23/1999
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
<i>KH</i>	AN2	WO 98/13368 A1	04/02/1998	WIPO			RECEIVED JUL 29 2002 TECH CENTER 1600/2900
	AO2	WO 99/30713 A1	06/24/1999	WIPO			Yes No
<i>✓</i>	AP2	WO 99/32150 A1	07/01/1999	WIPO			Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

<i>KH</i>	AR	<u>16</u>	Dennis, M.S., et al., "Binding Interactions of Kistrin With Platelet Glycoprotein IIb-IIIa: Analysis by Site-Directed Mutagenesis," <i>Proteins</i> 15:312-321, Wiley-Liss (1993)
	AS	<u>16</u>	Fabry, M.E., et al., "Second generation knockout sickle mice: the effect of HbF," <i>Blood</i> 97:410-418, American Society of Hematology (January 2001)
	AT	<u>16</u>	United States Pharmacopeia/ The National Formulary for 1995, published by United States Pharmacopeial Convention, Inc., Rockville, Maryland, p. 1636 (1994)

EXAMINER

*Al May Jr.*DATE CONSIDERED *Aug. 27, 2003*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> JUL 26 2002		ATTY. DOCKET NO. 1503.1030002/JMC/THN	APPLICATION NO. 10/058,215
		APPLICANT Lu et al.	
		FILING DATE January 29, 2002	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
KM	AL3 WO 99/43651 A2	09/02/1999	WIPO			Yes No
KM	AM3 WO 01/58893 A2	08/16/2001	WIPO			X Yes No
AN						Yes No
AO						Yes No
AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

KM	AR	17	Dialog File 351, Accession No. 14058279, Derwent WPI English language abstract for WO 01/58893 A2 (Document AM3)
	AS		
	AT		

EXAMINER

*John M. Mori*

DATE CONSIDERED

*Aug. 27, 2003*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.